Cytokinetics’ CK-274 Appears To Upstage BMS’s Newly Acquired Mavacamten

Phase III Trial To Start By Year’s End

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

The REDWOOD-HCM study showed early, sustained efficacy and no serious adverse events with a drug Cytokinetics designed to be superior to mavacamten, a drug it spun out via BMS-acquired MyoKardia.

Cardiology vector illustration; cardiomyopathy
Echocardiograms at multiple timepoints showed efficacy in both CK-274 cohorts • Source: Alamy

Cytokinetics, Inc. reported results from the 41-patient Phase II REDWOOD-HCM clinical trial on 19 July that appear to show better efficacy and improved safety with the cardiac myosin inhibitor CK-274 in the treatment of obstructive hypertrophic cardiomyopathy (oHCM) relative to mavacamten, a similar drug now owned by Bristol Myers Squibb Company that is under US Food and Drug Administration review with an approval decision expected in January.

The placebo-controlled REDWOOD-HCM trial was conducted to assess safety and efficacy in oHCM patients and to identify a range of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D